Hoersholm, Denmark, March 10th 2016
Hoersholm, Denmark, March 10th, 2016 – Oncology Venture Sweden AB (OV:ST) today announced that the first patient has been included in the screening protocol for APO010 in Multiple Myeloma. This patient has entered the study at the first out of four planned participating Danish hematology sites where approximately 150 patients will be screened using OV’s DRPTM (Drug Response Predictor). The DRPTM uses genomic information from the individual cancer patient’s tumor. The screening will identify 15 patients with the highest likelihood to benefit from treatment with APO010. These 15 Multiple Myeloma patients will then be included in a focused phase 2 multi-center study. If the product already in stock is approved, the phase 2 study is expected to start Q2-Q3 2016. APO010 is a first-in-class FAS-ligand anticancer product in the immuno-oncology field.